Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Treatment Found to Effectively Reduce Inflammation

By BiotechDaily International staff writers
Posted on 03 Oct 2012
Recent research has found additional evidence that a simple solution, which is already used in intravenous drips, is an effective treatment for reducing inflammation.

The researchers also identified that hypertonic solution can ease inflammation purely through bathing in it--validating that the Victorians were correct to visit spa villages to “take the waters” for disorders such as rheumatoid arthritis.

The research team, led by Dr. Pablo Pelegrin, from the University of Manchester (UK), was examining how cell swelling can regulate inflammation; the immune system’s first response to injury or infection. They discovered that white blood cells (WBCs) swell in a similar way to how tissue swells around a wound. The investigators then went on to look at what causes the swelling.

The researchers injected solutions with low ions into mice. They discovered that these solutions acted as a danger signal, causing cells to swell. The swelling then activates a group of proteins called NLRP3, which then release inflammatory mediators. These trigger neighboring cells to increase inflammation. However, when a hypertonic solution was administered to the mouse, it drew the water out of the cells shrinking them back to their original size. This in turn deactivated the signal for inflammation.

Dr Pelegrin’s research provides further evidence for the use of hypertonic fluid therapy for the reduction of inflammation in the brain, a treatment that can reduce the amount of damage caused by disorders such as stroke and epilepsy. His team has been able to show for the first time why the solution works at a molecular level.

Dr. Pelegrin said, “Hypertonic solutions have been used in the treatment of stroke for many years. Clinicians have found that their use not only reduces brain swelling, but also alleviates brain inflammation. However, because there wasn’t a molecular target for hypertonic solutions there has been a lot of debate about the clinical effect. Here we have identified a target for hypertonic solutions by blocking the NLRP3 inflammasome which triggers inflammatory mediators at a molecular level.”

The investigators also looked at the benefits of hypertonic solutions when used outside of the body. They soaked bandages in the solution before using them on the legs of mice. They also evaluated bathing the inflamed area in a hypertonic solution, and in both cases, the inflammation was reduced. It appears the hypertonic solution produces an osmotic gradient through the skin, which clarifies why hot springs, which have a hypertonic composition, can ease the pain of ailments such as rheumatoid arthritis.

Vincent Compan worked with Dr. Pelegrin on this research in the faculty of life sciences. He remarked, “This research opens up exciting opportunities for the use of hypertonic solution as a treatment for inflammatory illnesses such as arthritis. What we’ve identified has the potential to be used to help so many patients.”

Another aspect of the investigators’ research identified that the signaling process to activate inflammation is one of the oldest evolutionary mechanisms. The researchers found that the same mechanism of cell swelling causes NLRP3 inflammasome activation in fish as well as mammals, meaning that it is one of oldest responses in the body leading to inflammation.

The research was published in the September 2012 issue of the journal Immunity.

Related Links:

University of Manchester




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.